Literature DB >> 27548410

The regulation of human hepatic drug transporter expression by activation of xenobiotic-sensing nuclear receptors.

David E Amacher1.   

Abstract

INTRODUCTION: If a drug is found to be an inducer of hepatic drug metabolizing enzymes via activation of nuclear receptors such as pregnane X receptor (PXR) or constitutive androstane receptor (CAR), it is likely that drug transporters regulated through these same receptors will be induced as well. This review highlights what is currently known about the molecular mechanisms that regulate transporter expression and where the research is directed. Areas covered: This review is focused on publications that describe the role of activated hepatic nuclear receptors in the subsequent regulation of drug uptake and/or efflux transporters following exposure to xenobiotics. Expert opinion: Many of the published studies on the role of nuclear receptors in the regulation of drug transporters involve non-human test animals. But due to species response differences, these associations are not always applicable to humans. For this reason, some relevant human in vitro models have been developed, such as primary or cryopreserved human hepatocytes, human liver slices, or HepG2 or HuH7 cell lines transiently or stably transfected with PXR expression and reporter constructs as well as in vivo models such as PXR-humanized mice. These human-relevant test systems will continue to be developed and applied for the testing of investigational drugs.

Entities:  

Keywords:  Drug transporters; human liver; nuclear receptors

Mesh:

Substances:

Year:  2016        PMID: 27548410     DOI: 10.1080/17425255.2016.1223626

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  11 in total

1.  A human xenobiotic nuclear receptor contributes to nonresponsiveness of Mycobacterium tuberculosis to the antituberculosis drug rifampicin.

Authors:  Ella Bhagyaraj; Drishti Tiwari; Nancy Ahuja; Ravikanth Nanduri; Ankita Saini; Rashi Kalra; Sumit Kumar; Ashok Kumar Janmeja; Pawan Gupta
Journal:  J Biol Chem       Date:  2018-01-22       Impact factor: 5.157

Review 2.  Contribution of Humanized Liver Chimeric Mice to the Study of Human Hepatic Drug Transporters: State of the Art and Perspectives.

Authors:  Anna Zerdoug; Marc Le Vée; Shotaro Uehara; Béatrice Lopez; Christophe Chesné; Hiroshi Suemizu; Olivier Fardel
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2022-07-06       Impact factor: 2.569

3.  Transcriptional Regulation of Solute Carrier (SLC) Drug Transporters.

Authors:  Shiwei Zhou; Yan Shu
Journal:  Drug Metab Dispos       Date:  2022-05-29       Impact factor: 3.579

4.  Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium.

Authors:  Raymond Evers; Micheline Piquette-Miller; Joseph W Polli; Frans G M Russel; Jason A Sprowl; Kimio Tohyama; Joseph A Ware; Saskia N de Wildt; Wen Xie; Kim L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2018-07-12       Impact factor: 6.875

5.  Epigenetic Regulation of Multidrug Resistance Protein 1 and Breast Cancer Resistance Protein Transporters by Histone Deacetylase Inhibition.

Authors:  Dahea You; Jason R Richardson; Lauren M Aleksunes
Journal:  Drug Metab Dispos       Date:  2020-03-19       Impact factor: 3.922

6.  Immunization and Drug Metabolizing Enzymes: Focus on Hepatic Cytochrome P450 3A.

Authors:  Kristina Jonsson-Schmunk; Romi Ghose; Maria A Croyle
Journal:  Expert Rev Vaccines       Date:  2021-03-18       Impact factor: 5.217

Review 7.  Membrane transporter data to support kinetically-informed chemical risk assessment using non-animal methods: Scientific and regulatory perspectives.

Authors:  Laure-Alix Clerbaux; Alicia Paini; Annie Lumen; Hanan Osman-Ponchet; Andrew P Worth; Olivier Fardel
Journal:  Environ Int       Date:  2019-03-08       Impact factor: 9.621

8.  Hepatic Transporter Alterations by Nuclear Receptor Agonist T0901317 in Sandwich-Cultured Human Hepatocytes: Proteomic Analysis and PBPK Modeling to Evaluate Drug-Drug Interaction Risk.

Authors:  Katsuaki Ito; Noora Sjöstedt; Melina M Malinen; Cen Guo; Kim L R Brouwer
Journal:  J Pharmacol Exp Ther       Date:  2020-03-03       Impact factor: 4.030

9.  Drug-resistance in doxorubicin-resistant FL5.12 hematopoietic cells: elevated MDR1, drug efflux and side-population positive and decreased BCL2-family member expression.

Authors:  Linda S Steelman; Steve L Abrams; Peter Ruvolo; Vivian Ruvolo; Lucio Cocco; Stefano Ratti; Alberto M Martelli; Luca M Neri; Saverio Candido; Massimo Libra; James A McCubrey
Journal:  Oncotarget       Date:  2017-12-06

10.  Genetic polymorphisms in PXR and NF-κB1 influence susceptibility to anti-tuberculosis drug-induced liver injury.

Authors:  Jingwei Zhang; Zhenzhen Zhao; Hao Bai; Minjin Wang; Lin Jiao; Wu Peng; Tao Wu; Tangyuheng Liu; Hao Chen; Xingbo Song; Lijuan Wu; Xuejiao Hu; Qian Wu; Juan Zhou; Jiajia Song; Mengyuan Lyv; Binwu Ying
Journal:  PLoS One       Date:  2019-09-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.